Charles Townsend - BioAdaptives COO Director
| BDPT Stock | USD 0.12 0.01 9.09% |
Insider
Charles Townsend is COO Director of BioAdaptives
| Age | 76 |
| Phone | 702 659 8829 |
| Web | https://www.shopbioadaptives.com |
BioAdaptives Management Efficiency
The company has return on total asset (ROA) of (3.4344) % which means that it has lost $3.4344 on every $100 spent on assets. This is way below average. BioAdaptives' management efficiency ratios could be used to measure how well BioAdaptives manages its routine affairs as well as how well it operates its assets and liabilities.BioAdaptives currently holds 450.26 K in liabilities. BioAdaptives has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioAdaptives until it has trouble settling it off, either with new capital or with free cash flow. So, BioAdaptives' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioAdaptives sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioAdaptives to invest in growth at high rates of return. When we think about BioAdaptives' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | INSIDER Age | ||
| Jiaming Li | Bit Origin | 35 | |
| Donald Young | Better Choice | 60 | |
| Sharla Cook | Better Choice | 43 | |
| Lionel Conacher | Better Choice | 61 | |
| Robert Sauermann | Better Choice | 32 | |
| Erick Minaya | Bit Origin | 53 | |
| Du Lianfei | Bit Origin | N/A | |
| Jinghai Jiang | Bit Origin | 46 | |
| Lucas Wang | Bit Origin | 41 | |
| Xia Wang | Bit Origin | 39 | |
Management Performance
| Return On Asset | -3.43 |
BioAdaptives Management Team
Elected by the shareholders, the BioAdaptives' board of directors comprises two types of representatives: BioAdaptives inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioAdaptives. The board's role is to monitor BioAdaptives' management team and ensure that shareholders' interests are well served. BioAdaptives' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioAdaptives' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Ellis, CFO Pres | ||
| Charles Townsend, COO Director | ||
| MD Jacobs, CEO Chairman |
BioAdaptives Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioAdaptives a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -3.43 | |||
| Operating Margin | (33.58) % | |||
| Current Valuation | 544.74 K | |||
| Shares Outstanding | 160.49 M | |||
| Shares Owned By Insiders | 7.39 % | |||
| Price To Earning | (14.28) X | |||
| Price To Sales | 7.53 X | |||
| Revenue | 19.78 K | |||
| Gross Profit | 10.11 K | |||
| EBITDA | (643.76 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioAdaptives Pink Sheet Analysis
When running BioAdaptives' price analysis, check to measure BioAdaptives' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAdaptives is operating at the current time. Most of BioAdaptives' value examination focuses on studying past and present price action to predict the probability of BioAdaptives' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAdaptives' price. Additionally, you may evaluate how the addition of BioAdaptives to your portfolios can decrease your overall portfolio volatility.